Nu-Med Plus (NUMD) Shareholder's Equity Growth (5y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nu-Med Plus | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -20.87% |
| Sep 30, 2025 | -25.93% |
| Jun 30, 2025 | -21.05% |
| Mar 31, 2025 | 8.54% |
| Dec 31, 2024 | 10.30% |
| Sep 30, 2024 | 7.58% |
| Jun 30, 2024 | 9.56% |
| Mar 31, 2024 | 5.58% |
| Dec 31, 2023 | -38.11% |
| Sep 30, 2023 | -21.78% |
| Jun 30, 2023 | -36.01% |
| Mar 31, 2023 | -34.12% |
| Dec 31, 2022 | -23.93% |
| Sep 30, 2022 | -51.60% |
| Jun 30, 2022 | -20.56% |
| Mar 31, 2022 | -38.83% |
| Dec 31, 2021 | 50.47% |
| Sep 30, 2021 | 12.51% |
| Jun 30, 2021 | -14.90% |
| Mar 31, 2021 | 22.45% |
| Dec 31, 2020 | 15.22% |
| Sep 30, 2020 | 24.79% |
| Jun 30, 2020 | 33.41% |
| Mar 31, 2020 | -15.86% |
| Dec 31, 2019 | 44.62% |
| Sep 30, 2019 | -41.35% |
| Jun 30, 2019 | -25.23% |
| Mar 31, 2019 | -23.91% |
| Dec 31, 2018 | 19.04% |
| Sep 30, 2018 | 27.24% |
| Jun 30, 2018 | 31.52% |
| Mar 31, 2018 | 30.40% |
| Dec 31, 2017 | 28.33% |
| Dec 31, 2016 | -585.16% |